The proliferation/migration ability mediated by CD151/PI3K/AKT pathway determines the therapeutic effect of hUC-MSCs transplantation on rheumatoid arthritis

References

• Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL, Lian Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Disease. 2016;7(1):e206. doi:10.1038/cddis.2015.327.
   Google Scholar
• Shin MJ, Park JY, Park JY, Lim SH, Lim H, Choi JK, Park CK, Kang YJ, Khang D. Inflammation-targeting mesenchymal stem cells combined with photothermal treatment attenuate severe joint inflammation. Adv Mater. 2023;14(12):1–12. doi:10.1002/adma.202304333.
   Google Scholar
• Giuliana MB, Marie M, Christian J, Noël D. Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells. Nat Rev Rheumatol. 2023;19(11):682–94. doi:10.1038/s41584-023-01010-7.
   PubMed Web of Science ®Google Scholar
• Djouad F, Bouffi C, Ghannam S, Noël D, Jorgensen C. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5(7):392–99. doi:10.1038/nrrheum.2009.104.
   PubMed Web of Science ®Google Scholar
• Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, Lam FF, Kang S, Xia JC, Lai WH, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121(9):1113–23. doi:10.1161/CIRCULATIONAHA.109.898312.
   PubMed Web of Science ®Google Scholar
• Nguyen PK, Neofytou E, Rhee JW, Wu JC. Potential strategies to address the major clinical barriers facing stem cell regenerative therapy for cardiovascular disease: a review. JAMA Cardiol. 2016;1(8):953–62. doi:10.1001/jamacardio.2016.2750.
   PubMed Web of Science ®Google Scholar
• Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell. 2020;11(10):707–22. doi:10.1007/s13238-020-00738-2.
   PubMed Web of Science ®Google Scholar
• Samakova A, Gazova A, Sabova N, Valaskova S, Jurikova M, Kyselovic J. The PI3k/Akt pathway is associated with angiogenesis, oxidative stress and survival of mesenchymal stem cells in pathophysiologic condition in ischemia. Physiol Res. 2019;68(Suppl 2):S131–38. doi:10.33549/physiolres.934345.
   PubMedGoogle Scholar
• Chen J, Crawford R, Chen C, Xiao Y. The key regulatory roles of the PI3K/Akt signaling pathway in the functionalities of mesenchymal stem cells and applications in tissue regeneration. Tissue Eng Part B Rev. 2013;19(6):516–28. doi:10.1089/ten.TEB.2012.0672.
   PubMed Web of Science ®Google Scholar
• Fathi E, Valipour B, Vietor L, Farahzadi R. An overview of the myocardial regeneration potential of cardiac c-Kit+ progenitor cells via PI3K and MAPK signaling pathways. Future Cardiol. 2020;16(3):199–209. doi:10.2217/fca-2018-0049.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106(6):1901–10. doi:10.1182/blood-2005-04-1417.
   PubMed Web of Science ®Google Scholar
• Walewska A, Janucik A, Tynecka M, Moniuszko M, Eljaszewicz A. Mesenchymal stem cells under epigenetic control - the role of epigenetic machinery in fate decision and functional properties. Cell Death Disease. 2023;14(11):720. doi:10.1038/s41419-023-06239-4.
   PubMed Web of Science ®Google Scholar
• Li S, Motiño O, Lambertucci F, Martins I, Sun L, Kroemer G. Protein regulator of cytokinesis 1: a potential oncogenic driver. Mol Cancer. 2023;22(1):128. doi:10.1186/s12943-023-01802-1.
   PubMed Web of Science ®Google Scholar
• Jiang T, Wang H, Liu L, Song H, Zhang Y, Wang J, Liu L, Xu T, Fan R, Xu Y. CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer. Mol Cancer. 2021;20(1):167. doi:10.1186/s12943-021-01474-9.
   PubMed Web of Science ®Google Scholar
• Verret B, Cortes J, Bachelot T, Andre F, Arnedos M. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019;30(Supp 10):x12–20. doi:10.1093/annonc/mdz381.
   PubMedGoogle Scholar
• Mill C, George SJ. Wnt signaling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res. 2012;95(2):233–40. doi:10.1093/cvr/cvs141.
   PubMed Web of Science ®Google Scholar
• Miller JR. The wnts. Genome Biol. 2002;3(1):1–15. doi:10.1186/gb-2001-3-1-reviews3001.
   Google Scholar
• Ding Y, Liang X, Zhang Y, Yi L, Shum H, Chen Q, Chan BP, Fan H, Liu Z, Tergaonkar V. Rap1 deficiency-provoked paracrine dysfunction impairs immunosuppressive potency of mesenchymal stem cells in allograft rejection of heart transplantation. Cell Death Disease. 2018;9(3):386. doi:10.1038/s41419-018-0414-3.
   PubMedGoogle Scholar
• Gálvez N, Bohmwald K, Pacheco GA, Andrade CA, Carreño LJ, Kalergis AM. Type I natural killer T cells as key regulators of the immune response to infectious diseases. Clin Microbiol Rev. 2021;34(2):1–8. doi:10.1128/CMR.00232-20.
   Web of Science ®Google Scholar
• Lucero L, Marta E. TNF-α and IFN-γ participate in improving the immunoregulatory capacity of mesenchymal stem/stromal cells: importance of cell-cell contact and extracellular vesicles. Int J Mol Sci. 2021;22(17):1–17. doi:10.3390/ijms22179531.
   Web of Science ®Google Scholar
• He X, Yang Y, Yao M, Yao M, Yang L, Ao L, Hu X, Li Z, Wu X, Tan Y, et al. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1298–304. doi:10.1136/annrheumdis-2020-217798.
   PubMed Web of Science ®Google Scholar
• Yao M, Chen Z, He X, Long J, Xia X, Li Z, Yang Y, Ao L, Xing W, Lian Q. Cross talk between glucose metabolism and immunosuppression in IFN-γ-primed mesenchymal stem cells. Life Sci Alliance. 2022;5(12):1–13. doi:10.26508/lsa.202201493.
   Web of Science ®Google Scholar
• Liang X, Ding Y, Zhang Y, Tse HF, Lian Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplant. 2014;23(9):1045–59. doi:10.3727/096368913X667709.
   PubMed Web of Science ®Google Scholar
• Gao Q, Jia F, Li X, Kong Y, Tian Z, Bi L, Li L. Biophysical cues to improve the immunomodulatory capacity of mesenchymal stem cells: the progress and mechanisms. Biomed Pharmacother. 2023;162(9):1045–59. doi:10.1016/j.biopha.2023.114655.
   Google Scholar
• Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley S, Hemler ME. Diminished metastasis in tetraspanin CD151-knockout mice. Blood. 2011;118(2):464–72. doi:10.1182/blood-2010-08-302240.
   PubMed Web of Science ®Google Scholar
• Margot Z. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9(1):40–55. doi:10.1038/nrc2543.
   PubMed Web of Science ®Google Scholar
• Takeda Y, Kazarov AR, Butterfield CE, Kaipainen A, Hemler ME. Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood. 2007;109(4):1524–32. doi:10.1182/blood-2006-08-041970.
   PubMed Web of Science ®Google Scholar
• Malla R, Marni R, Chakraborty A. Exploring the role of CD151 in the tumor immune microenvironment: Therapeutic and clinical perspectives. Biochim Biophys Acta Rev Cancer. 2023;1878(3):188898. doi:10.1016/j.bbcan.2023.188898.
   PubMed Web of Science ®Google Scholar
• Erfani S, Hua H, Pan Y, Zhou BP, Yang XH. The context-dependent impact of integrin-associated CD151 and other tetraspanins on cancer development and progression: a class of versatile mediators of cellular function and signaling, tumorigenesis and metastasis. Cancers (Basel). 2021;13(9):9–15. doi:10.3390/cancers13092005.
   Web of Science ®Google Scholar
• Peng D, Zuo H, Liu Z, Qin J, Li P, Wang D, Zeng H, Zhang X. The tetraspanin CD151‑ARSA mutant inhibits angiogenesis via the YRSL sequence. Mol Med Rep. 2023;28(4):1–8. doi:10.3892/mmr.2023.13069.
   Web of Science ®Google Scholar
• Gao C, Jia W, Xu W, Wu Q, Wu J. Downregulation of CD151 restricts VCAM-1 mediated leukocyte infiltration to reduce neurobiological injuries after experimental stroke. J Neuroinflammation. 2021;18(1):118. doi:10.1186/s12974-021-02171-6.
   PubMed Web of Science ®Google Scholar
• Kuhn NZ, Tuan RS. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. J Cell Physiol. 2010;222(2):268–77. doi:10.1002/jcp.21940.
   PubMed Web of Science ®Google Scholar
• Sbrana FV, Cortini M, Avnet S, Perut F, Columbaro M, Milito AD, Baldini N. The role of autophagy in the maintenance of stemness and differentiation of mesenchymal stem cells. Stem Cell Rev Rep. 2016;12(8):621–33. doi:10.1007/s12015-016-9690-4.
   PubMedGoogle Scholar
• Ma L, He X, Wu Q. The molecular regulatory mechanism in multipotency and differentiation of Wharton’s jelly stem cells. Int J Mol Sci. 2023;24(16):1–14. doi:10.3390/ijms241612909.
   Web of Science ®Google Scholar
• Xia C, Yin S, To KK, Fu L. CD39/CD73/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22(1):44. doi:10.1186/s12943-023-01733-x.
   PubMed Web of Science ®Google Scholar
• Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell. 2016;30(3):391–403. doi:10.1016/j.ccell.2016.06.025.
   PubMed Web of Science ®Google Scholar
• Tang T, Huang X, Lu M, Zhang G, Han X, Liang T. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. Cancer Res. 2023;14(1):3364. doi:10.1038/s41467-023-38578-3.
   Google Scholar